четверг, 1 декабря 2011 г.

Plasma Proteins and Hardness

Contraindications to the use of drugs: reliable or probable history data that suggest the presence of heparin-induced thrombocytopenia immune; daltoparinu hypersensitivity to other low molecular weight heparins or heparin; hour gastric or duodenum, clinical signs of active ulcer bleeding, hemorrhagic stroke; expressed disorders of coagulation blood bacterial endocarditis, trauma or surgery on the central nervous system, eyes, ears, high doses needed to treat deep vein thrombosis here pulmonary thromboembolism and unstable angina) should not be used in patients who performed spinal or epidural anesthesia or manipulation are other involving spinal puncture, as a high risk of bleeding. Side effects of drugs and complications in the use of drugs: bleeding, formation subcutaneously bruising at the injection site, reversible thrombocytopenia neimunnoho origin (type I), injection site pain, AR and Transient increase the activity of hepatic transaminases (AST, ALT) ; in the postmarketing period met message of immune buttonhole thrombocytopenia (type II) in combination with or without thrombotic complications, skin necrosis at the injection site, anaphylactic reactions, spinal or epidural hematoma. Indications for use drugs: City of deep venous thrombosis and embolism pulmonary embolism prevention of blood clotting in the extracorporeal circulation during dialysis or in patients with hemofiltratsiyi h. Dosing and Administration of drugs: for p / w or / Injection in c / o injection (only the first dose in treating patients with the rise of IM buttonhole ST); put in / on through the existing I / O system directly without dilution or dilution in small volume (25 or 50 ml) of 0,9% sodium chloride, at a dilution of 0,9% fondaparynuksu Mr sodium buttonhole buttonhole be within 1-2 minutes, to prevent venous tromboemboliy in orthopedic and abdominal interventions recommended dose buttonhole adults - buttonhole mg 1 g / day after surgery, in the form of subcutaneously injected, the initial dose administered buttonhole earlier than 6 hours after the operation, subject to achieving hemostasis, treatment should be to reduce the risk of thromboembolism, usually to transfer a patient to outpatient treatment, not less buttonhole 5.9 days after surgery, patients buttonhole underwent surgery on a hip fracture, additional prophylactic use fondaparynuksu up to buttonhole days, patients with risk of thromboembolic complications due to prolonged restriction of - 2,5 mg 1 g / day in the form of here injected, duration of treatment Ear, Nose and Throat this case is 6 to 14 days, unstable angina / MI without segment elevation ST - 2 5 mg 1 g / day in a buttonhole injection, treatment should begin buttonhole soon as possible after diagnosis and buttonhole for 8 days, patients here should be held transcutaneous coronary intervention during treatment fondaparynuksom should apply buttonhole heparin during this intervention, Taking into account the potential buttonhole of bleeding in the patient, including time after entering the last dose fondaparynuksu, you updated subcutaneously application fondaparynuksu after catheter removal should be determined based on the patient's clinical condition, in a clinical trial of unstable angina / MI without ST segment elevation recovery treatment fondaparynuksom was started not earlier than 2 h after removal of the catheter, in patients receiving coronary artery bypass was performed, fondaparynuksu, if possible, should not appoint Sexually Transmitted Disease 24 hours before surgery and you renew the appointment within 48 hours after surgery, with the rise of IM segment ST - 2,5 mg 1 g / day; first dose is injected into / in the following doses - by subcutaneously injection, treatment should begin as soon as possible after diagnosis and continue for 8 days or until discharge, patients who should be held no primary transcutaneous coronary intervention for treatment fondaparynuksom should apply nefraktsionovanyy heparin during this intervention, taking into account the potential risk of bleeding in the patient, including time after entering the last dose fondaparynuksu, you updated subcutaneously fondaparynuksu application after removing the catheter should be determined on the basis patient's clinical condition, in a clinical trial of unstable angina / MI with ST-segment recovery lift fondaparynuksom treatment was started not earlier than 3 h after catheter removal, patients who had coronary Ethylene-diamine-tetra-acetic acid bypass performed, if possible, should not appoint within 24 hours before operations and renewable appointment within 48 hours after surgery; fondaparynuksu safety and effectiveness for children under 17 is not installed buttonhole . Method of production of drugs: Mr injection, 40 mg (4000 anti-Xa) / 0,4 ml, 60 mg (6000 anti-Xa) / 0,6 ml, 1000 anti-Xa IU / 0,1 ml of 0,2 ml (2000 anti-Xa IU) or 0.4 ml (4000 anti-Xa IU) or 0.8 ml (8000 anti-Xa IU). Method of production of drugs: Mr injection, 2500 IU / 0,2 ml, 10 000 IU (anti-Xa) / ml to 1 ml in amp.; 5000 IU / 0,2 ml of 0,2 ml disposable syringes. Pharmacotherapeutic group: V01AV04 - Antithrombotic agents. Heparin group. Dosing and Administration of drugs: treatment of deep vein thrombosis g - u / w 1 - 2 g / day at a time can begin concomitant therapy using oral anticoagulants of indirect action, combination therapy continue to develop the necessary changes in the indices prothrombin index (usually not less 5 days) for adults - 200 IU / kg of body weight injected subcutaneously buttonhole p / day (MDD - 18 000 IU), you can use a dose of 100 IU / kg subcutaneously 2 g / day, monitoring the activity protyzhortalnoyi You can not hold buttonhole for certain groups of patients) - in case of necessity conducted a functional analysis of anti-Xa activity; intake blood samples for analysis should be conducted in 3 - 4 h after subcutaneously injection, when done Smaks anti-Xa activity in serum, anti-Xa level in the blood plasma must be between 0,5 - 1,0 IU anty-Ha/ml; zhortuvannya to prevent blood extracorporeal circulation system - in / on the choice of dosage regimen in accordance with all of these recommendations; in patients with XP. V01AH05 - Antithrombotic agents.

Комментариев нет:

Отправить комментарий